Optimal timing and duration of induction therapy for HIV-1 Infection
2007

Optimizing HIV-1 Induction Therapy Timing and Duration

publication Evidence: moderate

Author Information

Author(s): Curlin Marcel E, Iyer Shyamala, Mittler John E

Primary Institution: University of Washington

Hypothesis

Can the timing and duration of induction therapy for HIV-1 be optimized to improve treatment outcomes?

Conclusion

The study suggests that 6–10 months of induction therapy is optimal for eradicating drug-resistant viruses and that starting induction therapy several days to weeks after maintenance therapy may enhance treatment success.

Supporting Evidence

  • Induction therapy lasting 6–10 months maximizes the chance of eradicating drug-resistant viruses.
  • Delayed-induction therapy can improve treatment outcomes by timing the start of strong medicine after maintenance therapy begins.
  • The model accounts for various factors affecting viral dynamics, including drug efficacy and resistance.

Takeaway

Doctors treating HIV want to use medicines in a way that helps patients without causing too many side effects. This study shows that giving strong medicine for a while before switching to easier medicine can help get rid of bad germs that resist treatment.

Methodology

A stochastic simulation model was used to analyze viral dynamics and treatment strategies for HIV-1.

Limitations

The model makes several simplifying assumptions, including ignoring drug redistribution and the effects of reversion of drug-resistant variants.

Digital Object Identifier (DOI)

10.1371/journal.pcbi.0030133

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication